Bonnie Y. Tse

About

Meet Ane-Kristine Finbraten: Harkness/Norwegian Institute of Public Health Fellow, Physician, and Researcher on Hepatitis C Elimination

—

Bonnie Tse

The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) is a research hub that is committed to improving substance use disorder treatment, policies, and care for people who use drugs. CHERISH is connected to more than 100 affiliated researchers across the U.S. To disseminate newly published work to researchers and policymakers, I share key findings through concise and informative research summaries and write profile series to amplify the experts in our network.

Commonwealth Fund Harkness Fellows can be placed anywhere in the United States. Ane-Kristine Finbraten, MD, PhD, photographed with her husband, chose New York City and CHERISH as her preferred placement.

Coming to New York City was an easy decision for Harkness Fellow Ane-Kristine Finbraten.

The city has one of the most robust hepatitis C elimination efforts to learn from. A founding member of the Centre for Elimination of Hepatitis C in Norway and an infectious diseases provider, Finbraten was elected as a 2021-2022 Commonwealth Fund Harkness/Norwegian Institute of Public Health Fellow to conduct original research and gain exposure to policy development in the United States.

“I wanted to understand more about policy work and learn how I can help more people by working at the health systems level,” Finbraten said. At the Centre for Elimination of Hepatitis C, Finbraten and her team document the hepatitis C elimination processes in Norway and develop treatment models to further the World Health Organization’s global initiative to eradicate viral hepatitis C. One treatment model in development is Opportuni-C, in which her team studies the effect of initiating rapid hepatitis C treatment for people who inject drugs and are hospitalized.

Read the full story at the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) published on March 17, 2022.